CAMBRIDGE, Mass. (AP) _ Editas Medicine Inc. (EDIT) on Tuesday reported a loss of $26.6 million in its third quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 64 cents.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 61 cents per share.
The genome editing company posted revenue of $6.3 million in the period, topping Street forecasts. Three analysts surveyed by Zacks expected $1.9 million.
Editas shares have climbed 42 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $23.06, a rise of 71 percent in the last 12 months.